Mylonib 15mg 60 Tablets

Mylonib 15mg is a targeted oral therapy designed for patients battling specific types of resistant blood cancers. This medication inhibits the proteins that drive the uncontrolled growth of white blood cells in the marrow. Order Mylonib from PakMeds to benefit from secure packaging and reliable delivery across all major cities in Pakistan.

Mylonib Ingredients and Usage

Mylonib contains Ponatinib, a small-molecule tyrosine kinase inhibitor (TKI) that addresses the genetic causes of leukemia. Each film-coated tablet delivers 15mg of the active pharmaceutical ingredient formulated for consistent daily dosing and absorption. The 60-tablet pack provides a standard supply for patients requiring specialized care for resistant blood disorders.

Oncologists prescribe Mylonib for adults with Chronic Myeloid Leukemia (CML) or Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL). It is particularly effective for patients who carry the T315I mutation, which resists other standard treatments. Patients should take one tablet daily at the same time, with or without food, as directed by their specialist.

How Does Mylonib Work?

Mylonib works by binding to and inhibiting the BCR-ABL protein, an abnormal tyrosine kinase produced by the Philadelphia chromosome. In many cases of leukemia, this protein acts like a permanent "on" switch, signaling white blood cells to divide uncontrollably. Mylonib blocks this switch, effectively halting the production of malignant cells and allowing healthy marrow function to return.

Unlike many earlier therapies, Mylonib is engineered to bypass common resistance mechanisms that often develop during long-term cancer treatment. It targets multiple variants of the ABL kinase, including the difficult-to-treat T315I mutation, ensuring a broader therapeutic impact. This dual action makes it a crucial choice for patients who have not responded to first-generation kinase inhibitors.

Mylonib Side Effects

Mylonib can cause cardiovascular changes and skin reactions that require close medical supervision and regular blood pressure monitoring. Most side effects are manageable, but patients should stay in constant contact with their oncology team to report any new symptoms.

• High blood pressure (Hypertension)

• Dry skin and rash

• Stomach pain or constipation

• Nausea and vomiting

• Fatigue and general weakness

• Headache and dizziness

• Muscle and joint pain

• Peripheral neuropathy (numbness)

• Fever or chills

• Decreased appetite

• Mouth sores and inflammation

• Swelling in hands or feet

Warnings

• Mylonib carries a significant risk of arterial thrombosis and heart attack, requiring careful cardiovascular assessment before and during therapy.

• Hepatotoxicity has been reported with Ponatinib; therefore, liver function tests must be monitored regularly throughout the entire treatment course.

• Heart failure and cardiac arrhythmias can occur, so inform your doctor immediately if you experience shortness of breath or palpitations.

• Severe hypertension is common and must be controlled before starting therapy and monitored weekly for the first eight weeks.

• Pancreatitis has occurred in some patients; your doctor will monitor serum lipase levels monthly to ensure your pancreas remains healthy.

• Severe hemorrhage and blood clots have been documented, necessitating immediate medical care for any unusual bleeding or sudden weakness.

• Mylonib can cause severe fetal harm; women of childbearing age must use highly effective contraception and avoid breastfeeding during treatment.

Tell your doctor about any history of stroke, high cholesterol, or blood vessel disease to ensure Mylonib is safe for you.

Mylonib Storage Conditions

Store Mylonib 15mg tablets at room temperature between 20°C and 25°C in a cool, dry environment. Keep the tablets in their original container to protect them from moisture and excessive heat, which can degrade the active ingredient. Always keep the bottle tightly closed and store it safely away from the reach of children and household pets.